| First character of title | Commenter | Comment Information |
A
|
Title: MD
Date: 12/10/2009
Comment:
I am a retired hematologist and very familiar with MDS and and great benifits of HSCT. I strongly reccommend that you approve Medicar payments for HSCT in patients with
More opens in new window
|
|
Date: 12/03/2009
Comment:
I would like to express my support of coverage for transplantS for patients with
More opens in new window
|
|
Date: 12/02/2009
Comment:
I am writing to urge coverage of allogeneic stem cell transplantation for Medicare patients with MDS. This is currently the only known curative treatment. Recent studies show that this treatment is effective for Medicare age
More opens in new window
|
|
Title: Professor of Medicine
Organization: Harvard Medical School
Date: 11/13/2009
Comment:
I have been a hematologist-oncologist for 25 years and I have witnessed many changes in MDS therapy and HSCT over that time. Clearly, allogeneic transplantation is no longer an age- limited procedure. I think the data are
More opens in new window
|
|
Date: 11/17/2009
Comment:
I ham a hematologist-oncologist specializing in stem cell transplantation. I feel very strongly that allogeneic stem cell transplantation if a valid indication for patients with MDS, regardless of their age, as long as they
More opens in new window
|
B
|
Title: MD
Date: 11/25/2009
Comment:
Allogeneic HSCT is the only known curative treatment for MDS and these patients have no other option. Medical management using medications can control the disease but not cure it.The longer they wait for this definitive
More opens in new window
|
|
Date: 12/02/2009
Comment:
It would seem to make sense to me like any mediacl problem that can be treated and controled early on would be cheaper then to let the problem develope worse and then treat it. Howard
More opens in new window
|
|
Date: 12/04/2009
Comment:
bone marrow transplant it is importatnt that we keep this as an option because of its valuable life saving needs please keep this in the medicare bill Thank
More opens in new window
|
|
Title: Professor of Medicine
Organization: University of California, San Diego
Date: 11/28/2009
Comment:
I have been a hematologist and bone marrow transplant specialist for over 25 years and currently direct the blood and marrow transplant program at the University of California, San Diego. I am writing to urge CMS to provide coverage
More opens in new window
|
|
Title: division administrator
Organization: washington university division of oncology
Date: 11/30/2009
Comment:
On behalf of investigators of the Siteman Cancer Center, the largest NCI-designated Comprehensive Cancer Center in the Midwest, and as one of the leading hematologic malignancy and stem cell transplantation programs in the world, we are writing
More opens in new window
|
|
Date: 12/10/2009
Comment:
Dear Sirs: I understand that you are charged to decide on what Medicare will cover, and one thing it should cover is stem cell transplantation as a treatment for certain cancerous blood diseases. This form of treatment has
More opens in new window
|
|
Title: Medical Director,
Organization: Bone Marrow and Stem Cell Transplant Program
Date: 11/18/2009
Comment:
Myelodysplastic Syndrome is a progressive disease of the elderly which is poorly treated with current therapeutic strategies. Allogeneic stem cell transplantation is the only known curative treatment for MDS. While a good number
More opens in new window
|
|
Title: Physician, Blood and Marrow Transplantation
Organization: Rocky Mountain Cancer Centers
Date: 11/13/2009
Comment:
Allogeneic hematopoietic stem cell transplantation is the only therapy with the potential to cure patients with myelodysplastic syndrome. Medicare's policy of not covering allogeneic transplantation for this indictation is
More opens in new window
|
|
Date: 12/10/2009
Comment:
Please consider approving medicare coverage for stem cell transplantation treatment of
More opens in new window
|
|
Date: 12/07/2009
Comment:
It is my understanding that HSCT transplants are the only curative treatement for MDS. I urge your group to consider coverage of these transplants for medically elegible medicare patients. Any disparity between between
More opens in new window
|
|
Date: 12/03/2009
Comment:
I am asking that stem cell transplantation be paid for in those that need it that have been diagnosed with MDS. [PHI Redacted] No one knows what will happen tomorrow. While most decision makers may not have dealth with certain
More opens in new window
|
|
Date: 12/08/2009
Comment:
To Whom It May Concern:
Our friend, [PHI Redacted] diagnosed with what was a dangerous form of MDS, in 2005 received an allogeneic stem cell transplant at M.D. Anderson Cancer Center. Today, she remains healthy and
More opens in new window
|
|
Date: 12/07/2009
Comment:
Much of the extraordinary expense in Medicare appears to arise from end of life care. I have read that 35 to 40 percent of health costs in this country relate to care within the last six months of life. I strongly agree that
More opens in new window
|
|
Title: EVP, Clinical Affairs and Strategic Planning
Organization: America's Health Insurance Plans (AHIP)
Date: 12/10/2009
Comment:
December 10, 2009
Lori Paserchia, MD
Medical Officer
Coverage and Analysis Group
Centers for Medicare and Medicaid Services
Mail Stop C1-09-06
7500 Security Boulevard
Baltimore, Maryland
More opens in new window
|
|
Title: Chair, Department of Hematologic Oncology and Bloo
Organization: Cleveland Clinic
Date: 11/30/2009
Comment:
To Whom It May Concern: Cleveland Clinic is a not-for-profit, integrated health care provider dedicated to patient care, teaching and research. We are pleased to have the opportunity to comment on coverage for Allogeneic Hematopoietic Stem
More opens in new window
|
|
Date: 12/03/2009
Comment:
Please make this procedure available through
More opens in new window
|
|
Organization: CMDP
Date: 12/03/2009
Comment:
This is a successful treatment that should be approved for all individuals needing
More opens in new window
|
|
Date: 12/03/2009
Comment:
Please support Medicare coverage for Myelodysplastic Syndrome. Thank
More opens in new window
|
|
Date: 12/10/2009
Comment:
Let's enact legislation to expand Medicare coverage for MDS patients. Support passage of HR 1230 which will allow bone marrow transplants for Americans diagnosed with MDS. Currently this is There are 20-30,000 people diagnosed
More opens in new window
|
|
Title: Director, BMT Program
Organization: Jewish Hospital Cincinnati
Date: 12/01/2009
Comment:
This represents the only potentially curable treatment option for these patients. It is not clear how you can deny this option to this select group of patients. There is ample evidence in the literature to support this
More opens in new window
|